High-intensity exercise after autologous stem-cell transplantation

MS-N178 · Exercise and rehabilitation · multiple-myeloma or lymphoma survivors after autologous transplant

Evidence at a glance

Question: Does an 18-week supervised high-intensity program improve fitness and fatigue beyond usual care after autologous transplantation?
Finding: No significant added benefit was found; both groups improved and nearly half of controls received substantial physiotherapy.
Evidence label: Negative randomized added-benefit evidence
Benefit: No demonstrated between-group fitness or fatigue advantage.
Certainty: Moderate for this program and context, tempered by control contamination.
Risk: A selected post-transplant population completed supervised training; detailed adverse-event counts were not verified in the accessible abstract.
Cancer-control boundary: Fitness and fatigue outcomes do not establish relapse or survival benefit.

What was studied

Adults with multiple myeloma or lymphoma recently treated with high-dose chemotherapy and autologous stem-cell transplantation.

Design and comparator: Single-blind multicenter randomized trial; 18-week supervised high-intensity exercise versus usual care.
Participants: 109 randomized.
Intervention: Individualized supervised high-intensity aerobic and strength training over 18 weeks; intervention participants attended 86% of sessions.
Primary outcome and follow-up: Cardiopulmonary fitness, strength and multidimensional fatigue after the program; a later report assessed 12-month effectiveness and cost-effectiveness.

What the study found

Fitness improved by roughly 16–25% in the intervention group and 12–19% in controls, and fatigue declined in both groups. No primary outcome differed significantly. Forty-seven percent of controls reported at least 10 physiotherapy sessions. Longer-term analysis found no significant effect or convincing cost-effectiveness.

Negative or uncertain findings: The trial did not show added benefit beyond usual care. Control-group rehabilitation likely reduced contrast but also reflects real-world access.

Limits and applicability

Results concern autologous—not allogeneic—transplant and supervised high-intensity rehabilitation after discharge. Timing, baseline fitness, transplant complications and usual-care rehabilitation differ across centers.

Funding and conflicts: Exact funding and conflict details were not re-extracted; registry and full reports were checked.

Safety context

Post-transplant exercise requires attention to infection precautions, cytopenias, cardiopulmonary toxicity, neuropathy, graft recovery and myeloma bone disease. Fever or acute decline warrants medical evaluation.

Questions for the care team

Has blood-count and infection recovery been sufficient for supervised training?
Are there myeloma bone lesions or neuropathy requiring load modification?
What rehabilitation is already included in usual transplant follow-up?

Primary sources

Last literature search: 29 October 2026. Record appraisal: 29 October 2026. This page is educational and does not replace individualized medical advice. Exercise prescriptions should be adapted to diagnosis, treatment, surgical restrictions, blood counts, cardiopulmonary status, neuropathy, fall risk and bone-metastasis location. Symptom or fitness improvement is not proof of tumor response, recurrence prevention or longer survival unless those outcomes were directly tested.